Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy — Update of the EORTC QLQ‐H&N35, Phase I

Abstract

Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision.

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Head and Neck Module, updated version: Preliminary psychometric data from Serbian laryngectomized patients

“…Afterward, a provisional updated module was created using the EORTC item bank. This provisional module contained 60 items, which were pilot‐tested with respect to their ease of understanding, comprehensiveness, and applicability on a group of patients with head and neck cancer . As a result, it was suggested that the QLQ‐H&N updated module should contain 43 items, with 27 old and 16 new or revised items .…”

Exploratory study of long‐term health‐related quality of life in patients with surgically treated primary parotid gland cancer

“…The fear of recurrences has been shown to be one of the major factors associated with patients' HRQOL . Interestingly, the HRQOL scores generally were not strongly associated with actual recurrence.…”

Oncologic treatment landscape for head and neck squamous cell carcinoma

“…In recent years, its assessment gained immense importance and found its way into numerous trials as an endpoint [2,6,11,17,18]. Our survey revealed that 56.5% of the ORL departments assess their patients' quality of life.…”

“…Apart from therapeutic effectiveness and toxicity, quality of life (QOL) has become an important treatment outcome [2,6,11,17,18].…”